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Struvite, a crystalline substance first identified in
the 18th century, is composed of magnesium ammo-
nium phosphate (MgNH4PO4 6H20). Ulex, a Swed-
ish geologist, is generally credited with introduction
of the term struvite in 1845; he coined the geological
expression "struvite" in honor of H. C. G. von
Stuve, a Russian diplomat and naturalist (1772—1851)
[11. Von Stuve had published one of the earliest
scholarly geological works in 1807 entitled "Mineral-
ogical Memoirs."
Struvite urinary stones have also been referred to
as "infection stones" and "triple phosphate" stones.
The term triple phosphate stems from early chemical
analyses of the stones which demonstrated the pres-
ence of calcium, magnesium, ammonium, and phos-
phate (i.e., three cations and one anion). Carbonate
ions were also commonly identified; they were as-
sumed to be associated with calcium as calcium
carbonate (CaCO3). Modern crystallographic analy-
ses have shown that human "struvite" stones are a
mixture of struvite (MgNH4PO4 6H20) and carbon-
ate-apatite (Ca10[P04]45 C03). Calcite (CaCO3) is ex-
tremely rare (we have found one calcite stone in
20,000 stone analyses) and may be an artifact. In
some stones, struvite may be more abundant,
whereas in other stones apatite may predominate.
There is good evidence (to be reviewed) to link the
formation of struvite and carbonate-apatite stones to
urinary infection. For the purpose of this review,
infection-induced stones are synonymous with stru-
vite and carbonate-apatite.
Historical background (Table 1)
Hippocrates was well aware of the association of
putrefying urine and stones 112—4]. He encouraged
the surgical drainage of perinephric abscesses by
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itinerant lithotomists, though he did not perform the
operation himself (perhaps because the mortality
was so high). Hippocrates is believed to have been
the first to recognize that high fluid intake increases
urine volume, which he also recognized as favorable
therapy. Marcet (1817) was perhaps the first to note
the association of ammonia-producing putrefaction
and urinary stones [2]. At the end of the 19th cen-
tury, the observations of Horton-Smith [5], Brown
[6], Kuster [7], and Rosevig [8] established the
cause and effect relationship between urinary infec-
tion and stones. Modern therapy has been primarily
surgical in nature—based upon the procedures origi-
nally described by Simon, Heineke, Morris, and
Kummel [2, 4]. The discovery of penicillin and sul-
fanilamide [9, 10] and the widespread use of anti-
microbial agents have markedly reduced the morbid-
ity and mortality previously associated with surgical
therapy.
Patho genesis
There are five primary types of commonly encoun-
tered urinary stones, i.e., calcium oxalate, calcium
phosphate, magnesium ammonium phosphate, uric
acid, and cystine. Calcium phosphate stones may
have variable molecular configurations. For exam-
ple, calcium phosphate may exist as brushite
(CaHPO4), hydroxyapatite [Ca10(P04)6 (OH)2] or
carbonate-apatite [CalO(PO4)E C03]. Numerous
strains of bacteria cause clinically significant infec-
tion in the urinary tract. The pathogenesis of infec-
tion-induced urinary stones can be more clearly de-
lined by three questions; namely 1) what type of
stones are formed in the presence of bacteria, 2)
what types of bacteria cause stones to form, and 3)
what is the biochemical mechanism of infection-in-
duced stones.
Clinical observations. Numerous clinical reports
attest to the association of urea-splitting bacteria,
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Table 1. Urinary stones: Historical contributions
Yr Contributor Finding
980—1037 A.D.
1649
1676
1720
1767
1797
1806
1817
1871
1872
1874
1879
1880
1889
1896
1897
1901
1902
1907
1922
1923
1925
1926
1929
1935
Avienna
Riolan
van Leeuwenhoek
Boerhaave
Morgani
Wollaston
Bassini
Marcet
G. Simon
Andrew and Callander
Dawson and Baker
W. Heineke
H. Morris
Kummel
Maclntyre
Horton-Smith
Brown
Kuster
Schmorl
Rosenow and Meissner
Rosevig
Hager and Magrath
J.B. Sumner
A. Fleming
G. Domagk
struvite, and carbonate (apatite)a stones [6—8, 11—
131.
The report by Brown in 1901 [8] is noteworthy.
Brown collected renal pelvic urine samples from
both kidneys of six patients with unilateral pelvic
stones and urinary infection. Urinary pH and bacte-
rial cultures were performed on each specimen, and
the urea-splitting character of each bacterial isolate
was determined. The stone-containing kidney was
removed surgically, and the stones were analyzed
chemically. The urine from the uninvolved kidney
was sterile and acidic in each case, whereas the
stone-containing kidney was infected with Proteus
(three cases), Staphylococcus a/bus (two cases), and
Calcium carbonate has been reinterpreted as carbonate-apatite.
E. coli communis (one case). The urine harboring the
Proteus and Staph ylococcal infections was alkaline
(as compared to its mate and the E. Co/i-infected
urine) and contained increased quantities of cellular
debris and protein. All strains of Proteus and both
strains of Staphylococcus split urea, and the stones
from these five patients were composed of struvite
and carbonate-apatite. Identical strains of bacteria
were isolated from the center of the stone and urine
in the three cases so studied. The urine from the
kidney infected with E. co/i was acidic, and the stone
from this kidney was composed of uric acid and
urates. Brown concluded from his studies that stru-
vite and carbonate-apatite formed as a consequence
of alkalinity and the increased ammonia that resulted
from the splitting of urea.
Brown's observation of increased quantities of
4800 B.C.
460—370 B.C.
Unknown
Hippocrates
Bladder stone recovered from Egyptian mummy of this era: "nidus' '—urid acid;
"shell' '—carbonate-apatite and struvite
"I will not cut persons laboring under stone but will leave this to be done by men who
are practitioners of this work."
Noted association of putrefying urine and stones; recommended consumption of large
quantities of water
Noted that when urine was white and limpid (sterile), stones were hard; when urine
was thick and ropy (infected), stones were soft
Described branched renal calculus
Discovered bacteria
Discovered urea in urine
Described purulent urine in pelvis and ureter in association with vesical calculus;
introduced concept of ascending infection
Accurately described calcium oxalate, magnesium ammonium phosphate, and cystine
calculi
Introduced concept of cystoscope
1) Described chemical technique for stone analysis, 2) stressed need to examine nidus
and shell of stone, 3) studied solubiity of stone-forming salts in urine, 4) stated, "At
some time before it is discharged, urine must always become alkaline as a result of
the ammonia evolved when the process of putrefaction began and that the alkalini-
zation thus produced is unavoidably attended with the precipitation of the phos-
phates contained in urine."
Performed first nephrectomy for calculus
Electively incised pyonephritic kidneys and removed stones; all three patients expired
Performed first successful pyelolithotomy
Performed first successful nephrolithotomy
Performed partial nephrectomy for stones
First demonstrated renal calculi with X-ray
Described Proteus species in urine
Demonstrated coexistence of "triple phosphate stones" and urea-splitting bacteria
Noted that urinary infection increased the organic content of urine; he suggested that
crystalline salts were deposited on the organic material
Described matrix concretions associated with urinary infection
Demonstrated experimentally that certain bacteria have a specific stone-forming
ability
Stressed importance of urea-splitting bacteria in calculous formation
Suggested that urease was basis of infection-induced stones
Isolated and crystallized urease enzyme from jackbeans
Discovered antimicrobial properties of penicillin
Discovered antimicrobial properties of prontosil (sulfanilamide)
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protein in the urine harboring urea-splitting bacteria
has been subsequently confirmed [14—16].
Other investigators have noted the association of
gelatinous or matrix stones and urea-splitting infec-
tion [17—21]. These matrix stones are composed of
mucoproteins, carbohydrates, cellular debris, and
crystals of struvite and apatite [22, 23]. There has
been an occasional report alluding to calculogenic
properties of bacteria that do not split urea [24, 251;
the accumulated clinical evidence, however,
strongly supports Brown's notions that only urea-
splitting bacteria are calculogenic and that such bac-
teria form struvite and carbonate (apatite) stones.
Stoichiometry. Most authorities believe that urine
must be supersaturated for crystallization to occur
126, 27]. Under physiologic conditions, urinary am-
monia increases in response to induced acidity [28].
When urine is physiologically alkaline, ammonia lev-
els are quite low. Increased levels of both alkalinity
and ammonia must be present for urine to be super-
saturated with respect to struvite [291; such condi-
tions occur only in the presence of ureolysis (Fig. 1).
Urinary saturation with respect to struvite has been
studied in several laboratories, and all found that
sterile urine was invariably undersaturated with re-
spect to struvite [27, 29—321.
Physiologic urine is intermittently supersaturated
with respect to calcium phosphate [33]. Thus, cal-
cium phosphate crystalluria is a common occur-
rence. Hydroxyapatite stones commonly occur (oc-
casionally in pure forms, but more commonly mixed
with calcium oxalate) in conditions associated with
sterile urine and increased urinary alkalinity, i.e.,
renal tubular acidosis, hyperparathyroidism, etc.
Under physiologic and sterile pathologic conditions,
the urinary excretion of bicarbonate andlor carbon-
ate is low or nonexistent—too low to result in the
formation of carbonate-apatite. The carbonate ions
that exist in carbonate-apatite come from the conver-
sion of bicarbonate into carbonate in an alkaline
environment. Concentrations of bicarbonate and car-
bonate and alkalinity sufficient to bring about crys-
tallization of carbonate-apatite occur only in the
presence of ureolysis.
Urease splits urea according to the following
equation:
0
urease
H2N—C—NH2 > 2NH3 + CO2.
Further hydrolysis yields:
H2O
NH3 + H2O NHt + OH-,
and CO2 + H2O H2CO3 H + HCO3 COT,
where pK of NH3 9.03, pK of HCOi = 6.33, and
pK of CO = 10.1 (?). Thus, stoichiometric consider-
ations are in agreement with the clinical observa-
tions, namely that struvite and carbonate-apatite
stones form only as a consequence of urease-induced
hydrolysis of urea. It is of interest that urease was
suggested to be the pathogenic basis of infection
stones by Hager and McGrath in 1925 [11]. In 1926,
J.B. Sumner isolated urease from the jackbean and
identified the enzyme as a protein [341. This was the
first enzyme to be isolated in pure form. For this
major achievement in enzyme chemistry, Sumner
received the Nobel prize in biochemistry in 1946.
Experimental data. Experimental data from in
vivo and in vitro models from several laboratories
support the clinical observations and stoichiometry.
In vitro studies from our laboratory show that both
urea and urease must be present for bacteria to form
stones [29]. Urease inhibitors prevent struvite crys-
tallization in the presence of both urea and urease.
Struvite crystals form only in the presence of alkalin-
ity induced by urease or ammonium hydroxide. Al-
kalinity induced in urine by sodium hydroxide brings
about crystallization of apatite but not struvite.
Thus, our data is in complete agreement with similar
in vitro studies reported by Elliot et al [31, 32].
Several investigators have shown experimentally
that urease-producing bacteria are the primary (if not
the sole) bacteria involved in infection-induced
stones [30, 35, 361. Experimental investigations in
vitro and in vivo suggest that sterile urine which is
undersaturated with respect to struvite may dissolve
struvite stones [29, 30, 32, 37—39]. Elliot [40] and
Stamey [41] have reported the dissolution of human
renal calculi. There is good clinical evidence to sug-
gest that Stamey's case was an infection-induced
stone that dissolved during prolonged antibiotic
treatment [41].
Experimental investigations by Braude, Sie mien-
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Fig. 1. The biochemical changes occurring during a two-hour
period following the addition of urease to normal human urine.
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ski, and Shapiro [421 suggest that not only does
urease cause struvite stones, but urease contributes
to the virulence of Proteus species. Braude et al
have shown that intrarenal injections of urease in
rats produces struvite renal stones within 24 hr and
that histological evidence of pyelonephritis occurs
following intravascular injection of urease. Both phe-
nomena occur in the absence of infection. Experi-
mental investigations from several laboratories con-
firmed Braude's work by showing that urease
inhibition will prevent the pyelonephritic changes
normally induced by Proteus urinary infection [43—
451. In these experiments, urease-inhibited Proteus
colonize the urinary tract without inducing patho-
logic change.
The clinical observation that urea-splitting infec-
tion is associated with increased quantities of urinary
colloids has not, to my knowledge, been studied
experimentally. The source of these mucoproteins
and their role in calculogenesis is incompletely
delineated.
Urease producers. The bacterial species Proteus,
Staphylococcus, Pseudomonas, and Klebsiella are
most commonly implicated clinically in calculogene-
sis. E. coli has been associated with stone formation
very rarely [24, 251. Data concerning the urease-
producing capability of various bacterial species has
been accumulated by Analytab Products, Inc. (200
Express Street, Plainview, N.Y. 11803). Examina-
tion of more than 120,000 bacterial isolates indicates
that E. coli rarely, or never, produces urease,
whereas Proteus species virtually always do so (Ta-
ble 2). Data concerning the incidence of urease pro-
duction by gram-positive bacteria is not, to my knowl-
Table 2. Urease producers
Organism % positives
P. vulgaris 99.6
P. mirabilis 98.7
P. morganii 91.8
P. rettgeri 99.0
Providencia al cahfaciens 99.0
Providencia stuarti 97. 1
Kiebsiella pneumoniae 63.6
Pseudomonas aeruginosa 32.6
Serratia marcescens 29.0
Serratia liquefaciens 5.0
Enterobacter aerogenes 2.6
Citrobacterfreundii 0
E. coli 0
aThe percent positive indicates the percent of bacterial isolates
that gave positive indication of urease activity when utilizing the
standardized assay system developed by Analytab Products Inc.
(API), 200 Express Street, Plainview, N.Y. 11803. The percent-
ages are based on more than 120,000 bacterial isolates accumu-
lated by API.
edge, available. Staphylococcus albus, however, is
thought to commonly produce urease. Bacterial frag-
ments (L-forms) may also produce urease [46].
Vicious cycle. Several reports attest to the diffi-
culty (and oftentimes impossibility) of eradicating
urinary infection in the presence of a stone [41, 47].
Residual stones and/or residual or persistent infec-
tion set the stage for recurrent stone formation.
Thus, a vicious cycle is created, whereby infection
causes growth of the stone, and the presence of
the foreign body (stone) harbors and perpetuates the
infection and blunts the effectiveness of antimicro-
bial therapy.
Thus, clinical, experimental, and stoichiometric
evidence supports specific answers to the three ques-
tions posed at the outset. Namely, struvite and car-
bonate-apatite stones form only as a consequence of
the hydrolysis of urea by urease. Only bacteria that
produce urease form such stones. Ureolysis by
urease increases urinary levels of ammonia, bicar-
bonate, carbonate, and pH. These chemical changes
bring about urinary supersaturation with respect to
struvite and carbonate-apatite, which results in crys-
tal formation. These changes are associated with an
increase in urinary proteins, which may also play a
role in calculogenesis. Elimination of the infection
and/or inhibition of urease may reverse the patholog-
ical process. Dissolution of infection stones is theo-
retically possible.
The role of non-urease-producing bacteria in the
pathogenesis of other types of urinary stones (i.e.,
calcium oxalate, hydroxyapatite, etc.) is incom-
pletely defined. There is no compelling evidence,
however, to suggest that such bacteria are
calculogenic.
Clinical manifestations
Infection stones account for 15 to 20% of all uri-
nary stones. Infection stones may occur as the pri-
mary event, or infection may induce further stone
formation on a pre-existing stone. Infection stones
commonly manifest as renal or bladder calculi but
infrequently as ureteral calculi.
Staghorn renal calculi (so-called because of their
branched configuration) are commonly (though not
always) infection-induced. Infected staghorn calculi
can grow rapidly. Such calculi often form with few, if
any, symptoms. Typically, a female presents with
recurrent symptoms of cystitis, and subsequent radio-
graphs demonstrate the asymptomatic renal calcu-
lus. Persistent and/or recurrent symptoms of pyelo-
nephritis may also herald development of the stone.
Bladder stones of struvite and carbonate-apatite
occur commonly in association with the long-term
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use of indwelling urethral catheters. Patients main-
tained on long-term catheter drainage are commonly
treated with various antimicrobial agents in a futile
attempt to sterilize their urine. The most antibiotic-
resistant organisms are ultimately selected by such
treatment, which all too often are urease-producing
Proteus or Pseudomonas.
Patients with spinal cord injury and/or neurogenic
vesical dysfunction seem particularly prone to the
development of infection stones [48—52]. Comarr,
Kawaichi, and Bors note an 8% incidence of renal
stones in more than 1,000 patients treated for spinal
cord injury; all stones analyzed contained struvite
[48]. The basis for the increased incidence in these
patients may be in part related to the antimicrobial
management described previously. Patients undergo-
ing ileal conduit diversion for benign or malignant
disease also tend to form struvite stones [50, 53].
Management
Diagnostic evaluation of the patient with urinary
stones and infection is directed toward 1) biochemi-
cal evaluation of blood and urine to ascertain the
presence of an underlying physiologic or metabolic
abnormality, 2) bacteriological evaluation of the ur-
ine to ascertain the type of organism and its antimi-
crobial sensitivities, 3) radiographic documentation
of the number, size, and location of the stones, and
4) radiographic documentation of anatomical abnor-
malities. If an infection-induced stone is suspected,
bacterial localization studies may be warranted.
Treatment is directed toward 1) surgical removal
of all of the stone and correction of anatomical
abnormalities, 2) eradication and/or long-term
suppression of urinary infection, and 3) specific
treatment of any underlying metabolic disorder. Pa-
tients with infected staghorn calculi who receive no
treatment have about a 50% chance of losing the
kidney [54, 55]. Patients with untreated bilateral in-
fected staghorn calculi are reported to have a 25%
mortality within five years and a 40% mortality
within ten years [541.
Surgical treatment. A review of the surgical tech-
niques involved in the removal of bladder and/or
ureteral calculi is beyond the scope of this text.
Renal calculi are commonly removed through a
parenchymal renal incision (nephrolithotomy) [56] or
through an incision into the renal pelvis (pyelolithot-
omy). Removal of large branched calculi may be
facilitated by use of an extended pyelolithotomy
[57]. The surgical goal is removal of all stone frag-
ments; some surgeons also advocate removal of lo-
calized segments of the renal parenchyma that are
obviously pyelonephritic [58—63]. Numerous adjunc-
tive surgical techniques have been developed to fa-
cilitate surgical success. These include: regional re-
nal hypothermia [64], operative radiography,
operative nephroscopy [65], coagulum pyelolithot-
omy [66, 67], and postoperative renal irrigations with
stone solvents [68—73]. Complete surgical removal
of all stone material, however, is not always possible
in even the most expert hands (Table 3). The opera-
tive mortality from such procedures is less than 1%,
and the surgical morbidity is small.
Surgical removal of the renal calculus, however,
may not be curative, for recurrent stone formation is
relatively common. There are few statistics available
by means of which to compare the prevalence of
recurrence and/or the morbidity of the recurrence
between infected and aseptic renal stones. Likewise,
no valid statistics are available to compare the preva-
lence of renal loss (nephrectomy). Table 3 summa-
rizes the mortality and prevalence of stone recur-
rence of a number of clinical series. Each series
contains both infection-induced and aseptic stones.
The series by Williams [74] is perhaps most notewor-
thy. This series is composed primarily of sterile
stones. Williams concludes that though the recur-
rence rate was high (80%) during twenty years of
follow-up, the morbidity was relatively low. Most of
these patients passed their stones spontaneously or
else tolerated their recurrent renal calculi without
significant mortality or morbidity.
Table 4 summarizes the incidence of recurrent
stones and persistent postoperative infection in se-
ries with predominantly infection-induced renal cal-
culi. These are selected series which, in many cases,
are an abstracted portion of larger series. I have
taken the liberty of recalculating the original author's
data in several instances in an attempt to gain insight
into the effectiveness of modern management of in-
fection-induced renal stones. The recalculated data
suggest that surgical removal of an infected renal
stone will result in "cure" of the infection in approxi-
mately 60% of cases. Persistent infection can be
expected in 40% of cases, and recurrent stone forma-
tion can be expected in about 30% of cases within six
years. There is little data available on the fate of
residual and/or recurrent infection stones. If recur-
rent infection stones are similar to untreated infec-
tion stones, then a nephrectomy rate greater than
50% is to be anticipated [54, 55]. It is also unclear as
to how many of those patients with persistent post-
operative infection ultimately develop recurrent
stones. Likewise, little information is available con-
cerning the morbidity of persistent infection and/or
stone recurrence. Review of these series leaves the
impression that nephrectomy and/or azotemia are
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Table 3. Unselected series of reports of renal lithotomy operations (pyelolithotomy and/or nephrolithotomy) for removal of renal stones
True Total
Residual recurrent recurrent Average
No. of Mortality stones stones stonesa follow-up
Yr Author operations % % % % yr
1915 Cabot and Crabtree 66 3.2 — — 49 —
[75]
1922 Barney [76] 35 5.7 — — 40 —
1924 Brongersma [77] 100 — — — 30 —
1924 Rovsing [78] 109 — — — 40 —
1937 Twinem [79] 202 — 8 — 25 —
1937 Oppenheimer [80] 141 7.1 23 21 39 4
1939 Spence and Baird [811 86 0 — — 38 —
1949 Priestly and Dunn [82] 340 3.0 — — 50" 5
1949 Hellstrom [83] 348 1—5 7 17 25 10b
1954 Sutherland [84] 195 — — — 46 10
1963 Williams [851 554 — — — 60 18
1965 Marshall, Lavengood, 50 4 26 — 9.5 4.8
and Kelly [86]
1968 Smith and Boyce [56] 138 4 5.4 9 9 6.2
1971 Myrvold and Fritjofs- 65 — — — 56 9)
son [87]
1971 Singh, Tresidder, and 54 — 22 5 5 7b
Blondy [881
1972 Barzilay and Kedar 146 — — — 33 9
[631
1972 Williams [74] 98 — — — 80 20
1973 Mahmood and Mor- 24 0 13 — — —
ales [891
1974 Wickham, Coe, and 100 0 24 7 7 1—4
Ward [64]
1974 Boyce and Elkins [901 100 0 5 15 20b 3
1974 Wojewski and Tarasz- 1729 — — — 22 10b
kiewiez [91]
Total 3229 10
a Recurrent stones = 1011/3229 = 31% within ten years (from recalculation of authors' data).
b Values are estimated from author's data.
Values are calculated from author's data.
infrequent sequelae of sterile renal stones, whereas
these are rather frequent sequelae of infection-in-
duced renal stones.
Medical treatment. Traditional medical therapy
plays an adjunctive role to surgery in the manage-
ment of infection stones, though Libertino et al have
suggested recently that medical therapy may be pref-
erable to surgical therapy in patients with infected
staghorn calculi in solitary kidneys [941. Underlying
metabolic abnormalities must be recognized and cor-
rected. Antibiotics are given preoperatively and
postoperatively in an attempt to eradicate the atten-
dant infection. Long-term (perhaps lifetime), low-
dose, culture-specific antibiotics are probably indi-
cated so long as cessation of such agents results in
reestablishment of the urinary infection. Periodic and
routine bacteriologic and radiographic follow-up is
mandatory.
The Shorr regimen (restriction of dietary phospho-
rus, supplemented with Basaijel to further reduce
intestinal phosphorus absorption) is of some success
in preventing recurrence and/or growth of infection
stones [951. This treatment presumably works by
reducing phosphaturia, which thereby reduces uri-
nary saturation with respect to struvite and calcium
phosphate.
Spec jfic antimicrobial therapy. The experimental
studies previously cited suggest that physiologic ur-
ine, which is undersaturated, should not support
stone growth and might bring about stone dissolu-
tion. Pharmacologic treatment, so as to render urine
undersaturated with struvite and calcium phosphate,
is therefore a desirable therapeutic goal. Elimination
of bacteria with antibiotics and/or inhibition of bacte-
rial urease can be expected to render urine under-
saturated with respect to struvite and should signifi-
cantly reduce (though not always to undersaturated
levels) the calcium phosphate saturation.
In 1972, I initiated a clinical protocol using anti-
biotics to attempt the dissolution of infection-in-
duced renal calculi associated with chronic urease-
producing bacterial infection. In 1975, clinical inves-
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Table 4. Selected series of reports of renal lithotomy operations (pyelolithotomy and/or nephrolithotomy) for removal of infected renal
stones
tigations using acetohydroxamic acid (AHA), an ef-
fective inhibitor of urease, were added to the ongoing
study. Experimental and preliminary clinical investi-
gations of AHA by our group have been reported
elsewhere [29, 30, 34, 43, 96].
Thirty-one patients who had renal stones but no
detectable underlying metabolic abnormalities with
urea-splitting urinary infection were treated with cul-
ture-specific antibiotics. Eight of 31 patients devel-
oped and maintained sterile urine (while on antibiot-
ics) for six months or longer. Partial or complete
stone dissolution occurred in five of these eight pa-
tients. The radiographic size of the stone has re-
mained unchanged in the other three patients.
Acetohydroxamic acid (AHA). The twenty-three
patients with recalcitrant urea-splitting infections
and renal stones were treated with AHA at a dose of
0.5 to 1.0 g per day in divided doses. Details of this
clinical trial are being published elsewhere [97]. Ev-
ery patient treated with AHA sustained a reduction
in his urinary alkalinity and ammonia (Figs. 2—4). Tn
several patients, treatment with AHA was used be-
fore and after surgical removal of staghorn renal
calculi (Fig. 5). Reductions in urinary alkalinity and
ammonia were significantly greater when obstructing
stones were removed and pockets of infection
drained. Combinations of AHA and culture-specific
antibiotics resulted in sterilization of the urine in
several cases in which previous treatment with anti-
biotics failed to achieve sterile urine. Several pa-
tients have been treated for as long as 30 months with
AHA without adverse side effects. Patients with re-
duced renal function (creatinine clearance 30 ml!
mm) have been treated for longer than 18 months
with a dose of 250 mg of AHA taken two or three
times daily. Side effects have been minimal. Head-
ache is relatively common during the first two days
of treatment. Symptoms disappear spontaneously or
Yr Author
Sterile Infected No. with Recurrent No. with Average
No. of postop postopa persistent stone5 recurrent follow-up
operations % % infection" % stone" yr
1924 Brongersma [77] — — — — 52
1924 Rovsing [78] 56 — — — 68
1937 Oppenheimer [801 69 — — — 56
1937 Twinem [79] 15 — — — 40
1939 Higgins [92] 200 — — — 80
1943 Chute and Suby [131 49 — — — 73
1949 Hellstrom [831 80 32 68 — 37
1954 Sutherland [84] 48 — — — 64
1968 Smith and Boyce [56] 129 69 31 40 9
1971 Myrvold and Fritzjofs- 26 23 77 20 42
son [87]
1971 Pedersen [58] 50 27 73 36 —
1971 Nemoy and Stamey [93] 14 92 8 1 0
1971 Singh, Tresidder, and 36 63 27 10 —
Blondy [88]
1973 Wojewski and Tarasz- 84 — — 64
kiewicz [91]
1974 wickham, Coe, and 74 — 0
ward [64]
1974 Boyce and Elkins [90] 60 63 36 22
31
11
11
0
54
15c
4U
be
6.2
9C
3.9
3
7
be
C Persistent postop infection = 129/315 = 41% (recalculated from authors' data).
Recurrent stones = 118/435 = 27% within 6.3 yr (recalculated from authors' data).
Values are estimated from authors' data.
Values are recalculated from authors' data.
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Fig. 2. Dose response af uriaary ammonia (.—.) in a 26-yr-old
paraplegic with an ileal conduit (creatinine clearance, 68 mI/mm)
following a single 500-mg dose of acetohydroxamic acid (AHA).
Fig. 3. Changes in urinary pH and ammonia induced in 23 pa-
tients during long-term treatment with acetohydroxamic acid
(AHA), 500 mg per os, twice daily. Open circles denote Proteus-
infected patients on no treatment; closed circles denote Proteus-
infected patients on AHA; rectangle enclosure mean values SD
of patient controls (N = 20) with sterile urine.
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in response to mild analgesics. A hemolytic anemia
occurred in three patients (all with reduced renal
function) treated with 1.0 to 2.0 g per day of AHA.
These patients are now on treatment with 500 to 750
mg of AHA per day without ill effect. Three other
patients with pre-existing varicose veins developed
superficial phlebitis in their lower extremities. None
sustained any emboli. The phlebitis resolved follow-
ing cessation of AHA and has not recurred since
reinstitution of AMA.
To date, significant stone dissolution has not oc-
curred in any patient receiving AHA. Stone recur-
rence and/or stone growth also has not occurred.
Longer periods of observation and additional investi-
gations of the pharmacokinetics and biologic toler-
ance of AHA are warranted.
Our clinical investigations with antibiotics and
AHA support Elliot [40] and Stamey's [41] conten-
tion that struvite stones, in many instances, may be
preventable and, in some instances, dissolvable.
Our investigations lend further support to the widely
held hypothesis that stones form primarily as a con-
sequence of urinary supersaturation. Therapy that
achieves sustained undersaturation will not support
calculogenesis and may facilitate stone dissolution.
Other urease inhibitors. In 1962, Kobashi, Hase,
and Uehara [98] noted that the hydroxamic acids
inhibit urease. Numerous hydroxamates have been
synthesized [37, 99—101]. All inhibit urease. Of the
hydroxamates studied biologically, AHA seems to
have the greatest pharmacologic potential [102]. Hy-
droxyurea and thiourea also effectively inhibit urease
[45, 103]. A complete review of urease inhibitors is
beyond the scope of this review. It seems likely,
however, that AHA or some other inhibitor of urease
will become clinically useful in the management of
patients with infection stones. Urease inhibitors may
also be of clinical use in the management of hepatic
insufficiency (hyperammonemia) [104—106] and per-
haps in other disease processes as well.
In conclusion, the association of putrefying urine
and stones has been known since antiquity. The
accumulated clinical and experimental evidence
points to the bacterial enzyme urease as the primary
calculogenic mechanism. The hydrolysis of urea by
urease increases urinary ammonia and alkalinity.
These substances damage tissue and thereby contrib-
ute to bacterial invasion and virulence. Increased
C
Fig. 5. Urinary ammonia in three patients with staghorn renal
calculi and chronic Proteus urinary infection who were treated
with acetohydroxamic acid (AHA) pre- and postoperatively. Bac-
tenuria persisted postoperatively in all three patients (two with
ileal conduits) despite radiographic absence of stones. Postopera-
tive treatment with AHA results in near normal levels of ammonia
excretion.
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Fig. 4. Urinary ammonia excretion in ten patients treated with
acetohydroxamic acid (AHA) at a dose of 500 mg twice daily.
Solid lines indicate patients with artificial collecting devices, i.e.,
Foley catheters, ileal conduits, or suprapubic tubes. Broken lines
indicate patients with intact urinary tracts.
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levels of urinary pH, ammonia, bicarbonate, and
carbonate bring about supersaturation of urine with
subsequent crystallization of struvite and carbonate-
apatite. It is likely that these crystals are formed by
no mechanism other than the hydrolysis of urea.
These pathological processes are accompanied by an
increased urinary excretion of colloids which may
also contribute to calculogenesis.
Bacteria that do not make urease do not contribute
to the formation of struvite and carbonate-apatite.
The role of such bacteria in the pathogenesis of other
types of stones is unclear but seems unlikely.
Surgical removal of infected renal calculi with or
without removal of focal areas of pyelonephritis is
practical and successful in most cases. Long-term
treatment with antimicrobial agents and/or urease
inhibitors can be expected to reduce the incidence of
stone recurrence and/or the growth of residual
stones. The long-term practicality, safety, and effi-
cacy of these agents, however, has not yet been
confirmed. Antimicrobial agents and/or urease inhib-
itors may contribute to the clinical dissolution of
infection stones in selected instances; this concept
also awaits further clinical confirmation.
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